Cantor Fitzgerald Estimates bluebird bio FY2025 Earnings

bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of bluebird bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the biotechnology company will post earnings per share of ($23.60) for the year. The consensus estimate for bluebird bio's current full-year earnings is ($27.17) per share.

Other analysts have also recently issued reports about the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $80.00 price target on shares of bluebird bio in a research report on Friday, November 15th. Bank of America downgraded bluebird bio from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Wells Fargo & Company lowered their price target on bluebird bio from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Wednesday, September 25th. StockNews.com started coverage on shares of bluebird bio in a research note on Friday, December 20th. They set a "sell" rating for the company. Finally, Barclays lifted their target price on shares of bluebird bio from $2.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday, December 31st. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $49.14.

bluebird bio Stock Down 2.8 %

NASDAQ:BLUE traded down $0.23 during mid-day trading on Wednesday, hitting $7.92. 230,926 shares of the company's stock were exchanged, compared to its average volume of 193,952. The company has a market cap of $76.93 million, a PE ratio of -0.21 and a beta of 0.68. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a one year low of $5.80 and a one year high of $38.40. The business has a fifty day moving average price of $8.12 and a 200 day moving average price of $12.07.

Institutional Investors Weigh In On bluebird bio

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. Geode Capital Management LLC increased its position in shares of bluebird bio by 3.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company's stock valued at $2,433,000 after purchasing an additional 166,771 shares during the last quarter. State Street Corp lifted its stake in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company's stock worth $1,996,000 after purchasing an additional 43,382 shares during the period. Verition Fund Management LLC purchased a new position in shares of bluebird bio in the third quarter worth approximately $42,000. Finally, Captrust Financial Advisors grew its position in bluebird bio by 48.2% during the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company's stock valued at $123,000 after buying an additional 77,293 shares during the period. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.